AST SpaceMobile, Inc. (ASTS): A Bull Case Theory
We came across a bullish thesis on AST SpaceMobile, Inc. (ASTS) on Substack by Steve Wagner. In this article, we will summarize the bulls' thesis on ASTS. AST SpaceMobile, Inc. (ASTS)'s share was trading at $26.24 as of May 15th.
A close up of a satellite in space, showing the advanced technology of communications systems.
AST SpaceMobile (ASTS) is transitioning from a developmental phase to a potential commercial breakthrough, following a solid first quarter that emphasized progress over profit. Despite minimal revenue of $0.6M—mainly from early-stage gateway sales and government milestones—the lack of service income is expected, as commercial deployment remains targeted for late 2025. Operating losses widened to $63.6M due to ramped-up R&D and satellite production, but ASTS's strengthened balance sheet, boasting $874M in cash after a $460M convertible note and $55M share offering, provides a clear funding runway through at least 2025.
The dilution risk is real but muted near-term given the $27/share conversion price. The company projects $50M–$75M in 2025 revenue, tied to commercial service activation. A promising $13.6M in Q1 ground infrastructure orders from telecom partners is expected to recur quarterly, signaling network readiness. ASTS also benefits from $63M in government contracts, validating both commercial and defense potential. With six satellites already in orbit and a goal of 60 by end-2026, the company plans to begin monthly launches by July 2025, supported by vertically integrated manufacturing capable of producing six satellites per month. Most critically, ASTS recently completed a historic milestone: the world's first successful two-way voice and video calls over 4G LTE via satellite to unmodified smartphones, in partnership with telecom giants like AT&T, Vodafone, and Rakuten. With 40+ mobile network operator agreements covering 2.4B subscribers, ASTS is gaining momentum. The coming quarters are critical; if services launch and gain user traction, ASTS could transform into a commercially viable disruptor in satellite communications.
AST SpaceMobile, Inc. (ASTS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 22 hedge fund portfolios held ASTS at the end of the fourth quarter which was 18 in the previous quarter. While we acknowledge the risk and potential of ASTS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ASTS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article was originally published at Insider Monkey.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
WST截止日期：Rosen Law Firm敦促損失超過10萬美元的West Pharmaceutical Services, Inc. (NYSE: WST)股東與法律事務所聯絡以瞭解有關其權利的資訊
紐約--(BUSINESS WIRE)--(美國商業資訊)-- 全球投資人權益法律事務所Rosen Law Firm提醒投資人，一名股東代表在2023年2月16日至2025年2月12日期間購買West Pharmaceutical Services, Inc. (NYSE: WST)證券的投資人提起了集體訴訟。West將自身描述為一家「專注於注射藥物包裝元件、密封解決方案及輸送系統的醫療用品公司」。 如欲瞭解更多資訊，請遞交 表格 、向Phillip Kim律師 寄送電子郵件 ，或致電866-767-3653聯絡我們。 指控內容：Rosen Law Firm正在調查對West Pharmaceutical Services, Inc. (NYSE: WST)在其業務營運方面誤導投資人的指控。 起訴書指稱，在整個集體訴訟期內，被告做出了虛假和誤導性陳述及/或未揭露：(1)儘管聲稱對客戶需求有清晰預判，並將業務阻力歸咎於COVID相關產品的臨時性去庫存，但West實際上在其高利潤率的高價值產品(HVP)組合中持續經歷著顯著的去庫存現象；(2) West的SmartDose裝置雖被標榜為高利潤率的成長型產品，但由於營運效率不彰，對West的利潤率造成了嚴重稀釋；(3)這些利潤率壓力引發了高昂重整活動的風險，包括West退出與長期客戶簽署的持續血糖監測(CGM)合約；以及(4)由於上述原因，被告關於West的業務、營運和前景的正面陳述具有重大誤導性和/或缺乏合理依據。訴訟稱，當市場瞭解真實詳情後，投資人蒙受了損失。 現在怎麼辦：您可能有資格參與針對West Pharmaceutical Services, Inc.的集體訴訟。如果有股東希望擔任該集體訴訟的原告代表，則必須在2025年7月7日之前向法院提出申請。原告代表是指代表其他集體訴訟成員主導訴訟的當事人代表。您無需參與此案即有資格獲得追償。如果您選擇不採取任何行動，您也可以保持缺席集體訴訟成員的身分。如欲瞭解更多資訊，請點選 此處 。 所有代理均為勝訴後取酬。股東無需支付任何費用或開支。 關於Rosen Law Firm：與Rosen Law Firm不同，一些就此等事宜發表公告的法律事務所並不會實際提起證券集體訴訟。身為股東權益訴訟領域公認的領導者， Rosen Law Firm 一直致力於協助股東挽回損失、改善公司治理結構，並追究公司高階主管的違法行為責任。自成立以來，Rosen Law Firm已經為股東挽回了超過10億美元的損失。 請在LinkedIn： 、Twitter： 或Facebook： 上關注我們，以瞭解最新情況。 律師廣告。先前案例不保證可獲致類似結果。 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
Business Wire
4 hours ago
- Business Wire
ELV Deadline: Rosen Law Firm Urges Elevance Health, Inc. (NYSE: ELV) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Elevance Health, Inc. (NYSE: ELV) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that, with the Medicaid redetermination process nearly complete, defendants represented to investors that they were closely monitoring cost trends associated with the redetermination process and that the premium rates Elevance was negotiating with states were sufficient to address the risk and cost profiles of those patients staying on Medicaid programs. While defendants acknowledged that Medicaid expenses were rising, they repeatedly assured investors that this was adequately reflected in Elevance's guidance for the year. These representations were materially false or misleading. In truth, the redeterminations were causing the acuity and utilization of Elevance's Medicaid members to rise significantly, as the members being removed from Medicaid programs were, on average, healthier than those who remained eligible for the programs. This shift was occurring to a degree that was not reflected in Elevance's rate negotiations with the states or in its financial guidance for 2024. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Elevance Health, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by July 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
Yahoo
8 hours ago
- Yahoo
Jim Cramer on AST SpaceMobile: 'Gotta Ring the Register a Little'
AST SpaceMobile, Inc. (NASDAQ:ASTS) is one of the 11 stocks Jim Cramer put under the microscope recently. A caller asked what Cramer thought of the company, and this is what Cramer said in response: 'Listen, sunshine, that stock is up like 50 points… yeah, this stock is straight up from 20s to the 50s. What we have to do is tomorrow we gotta ring the register a little bit and say to ourselves, congratulations, and go buy yourself something fabulous, okay? Because you just hit it out of the park.' An aerial view of a communications satellite in orbit, beaming its signal down to Earth. AST SpaceMobile (NASDAQ:ASTS) develops the BlueBird satellite constellation to deliver space-based cellular broadband that connects directly to smartphones. The company's service targets users beyond the reach of traditional ground-based networks, including commercial and government applications. On March 28, the company was mentioned by Cramer when he said: 'The biggest problem is that they've got a hideous balance sheet, and I don't like hideous balance sheets. What has to happen is I think they should take on a partner. I do think that they've got a very interesting way to- look it's a good telecom company partner, but what really matters to me is they've got to either start making money or get someone to give them some money. Right now, I think you're too up in the air in this particular stock market.' While we acknowledge the potential of ASTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
